LEXINGTON, Mass. & SYDNEY--(BUSINESS WIRE)--GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides an innovative treatment for type 2 diabetes and obesity, today announces the appointment of Jim Murphy to the position of chief financial officer.
Murphy’s role will encompass the finance, accounting and administrative functions of the Company. He will also serve as the Company’s treasurer and secretary effective immediately.
The Company’s CEO Scott Schorer said, “Last week, GI Dynamics announced to shareholders it had completed a full review of systems, expenses and personnel. In line with that review, important changes will be made to the company’s senior management team as we work toward rebuilding GI Dynamics and saving EndoBarrier Therapy for the millions of patients suffering from type 2 diabetes and obesity.
“On behalf of the GI Dynamics board, I am delighted to announce the appointment of Mr. Murphy. We look forward to restarting the company with a strengthened senior management team.
“Mr. Murphy is an accomplished senior finance executive with more than 30 years of experience in high-growth domestic and international environments and with deep experience in the life science sector. Jim has demonstrated success in both small and large business settings, with extensive experience in raising capital, operations, and mergers and acquisitions. We are confident that GI Dynamics will benefit from his strategic and tactical leadership.”
“I joined GI Dynamics after speaking with the board and CEO,” stated Murphy. “It became clear that the technology developed at GI Dynamics has the potential to significantly help patients and clinicians fight a terrible disease and increase shareholder value. I look forward to working with the team at GI Dynamics.”
Prior to joining the Company, Murphy served as CFO of OXiGENE, Inc., a NASDAQ-listed drug discovery company, and CFO of HemaSure, Inc., a NASDAQ-listed medical device company that was spun out of Sepracor, Inc. Murphy was instrumental in the sale of HemaSure assets to Whatman Plc and was then part of a global team at Whatman that effected the consolidation of 18 operating locations worldwide to nine.
About GI Dynamics
GI Dynamics, Inc. (ASX: GID) is the
developer of EndoBarrier®, the first endoscopically delivered
device therapy approved for the treatment of type 2 diabetes and
obesity. EndoBarrier is approved and commercially available in multiple
countries outside the United States. EndoBarrier is not approved for
sale in the United States and is limited by federal law to
investigational use only in the United States. Founded in 2003, GI
Dynamics is headquartered in Lexington, Massachusetts. For more
information, please visit www.gidynamics.com.
Forward-Looking Statements
This announcement contains
forward-looking statements concerning: our development and
commercialization plans; our potential revenues and revenue growth,
costs, excess inventory, profitability and financial performance; our
ability to obtain reimbursement for our products; our clinical trials,
and associated regulatory submissions and approvals; the number and
location of commercial centres offering the EndoBarrier; and our
intellectual property position. These forward-looking statements are
based on the current estimates and expectations of future events by the
management of GI Dynamics, Inc. as of the date of this announcement and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those indicated
in or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to: risks associated with the
consequences of terminating the ENDO Trial and the possibility that
future clinical trials will not be successful or confirm earlier
results; risks associated with obtaining funding from third parties;
risks relating to the timing and costs of clinical trials, the timing of
regulatory submissions, the timing, receipt and maintenance of
regulatory approvals, the timing and amount of other expenses, and the
timing and extent of third-party reimbursement; risks associated with
commercial product sales, including product performance; competition;
risks related to market acceptance of products; intellectual property
risks; risks related to excess inventory; risks related to assumptions
regarding the size of the available market, benefits of our products,
product pricing, timing of product launches, future financial results
and other factors including those described in our filings with the U.S.
Securities and Exchange Commission. Given these uncertainties, you
should not place undue reliance on these forward-looking statements. We
do not assume any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, unless required by law.